GlassScriptPhysician profile
Tyler Rodman Mcvay
NPI 1245573815
$3,184.83
in general payments reported to CMS, 2019-2025
30 companies · $404 in 2025
The $404 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.61 · 2020: $281 · 2021: $418 · 2022: $506 · 2023: $673 · 2024: $815 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,791 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62.50 · Education: $38.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,790.89 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62.50 |
| Education | $38.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $630.68 | 2019-2025 | Entyvio, Eohilia |
| Abbvie INC. | $585.77 | 2019-2025 | |
| Medtronic, INC. | $289.53 | 2023-2024 | Gi Genius |
| Intercept Pharmaceuticals, INC. | $167.31 | 2022-2024 | |
| Janssen Biotech, INC. | $153.21 | 2020-2024 | Stelara, Tremfya |
| Genzyme Corporation | $152.00 | 2022-2025 | |
| Pfizer INC. | $149.77 | 2022-2025 | |
| Gilead Sciences, INC. | $135.53 | 2019-2024 | |
| Redhill Biopharma INC. | $124.12 | 2020-2023 | |
| Braintree Laboratories, INC. | $108.70 | 2020-2025 | Suflave, Sutab |
| Boston Scientific Corporation | $69.94 | 2025 | Spyglass |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.31 | 2021-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $63.86 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $62.50 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $41.84 | 2022-2023 | Dupixent |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $38.46 | 2023 | Yuflyma |
| Qol Medical, LLC | $38.25 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $36.58 | 2020-2021 | |
| Capsovision, INC. | $35.42 | 2023-2025 | Capsocam Plus |
| Ardelyx, INC. | $33.87 | 2025 | Ibsrela |
| Celgene Corporation | $27.39 | 2022-2024 | Zeposia |
| Mylan Institutional INC. | $26.14 | 2023 | Hulio |
| Ipsen Biopharmaceuticals, INC | $22.07 | 2025 | Iqirvo |
| Azurity Pharmaceuticals, INC. | $21.98 | 2025 | Suflave |
| Organon LLC | $21.17 | 2023 | Renflexis |
| Lilly USA, LLC | $19.63 | 2024 | Omvoh |
| Olympus America INC. | $18.66 | 2021 | |
| Ethicon US, LLC | $16.20 | 2023 | Linx Reflux Management System |
| Daiichi Sankyo INC. | $13.57 | 2021 | |
| Shionogi INC | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Mcvay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.